BUDESONIDE + FORMOTEROL TURBUHALER

Class: Beta2-Adrenergic Agonist, Long-Acting; Corticosteroid

Indications:

- Treatment of asthma in patients ≥12 years of age where combination therapy is indicated; maintenance treatment of airflow obstruction associated with chronic obstructive pulmonary disease (COPD; including chronic bronchitis and emphysema)

-Unlabeled Use :Treatment of asthma in children 5-11 years of age where combination therapy is indicated

Available dosage form in the hospital:

-BUDESONIDE 160MCG + FORMOTEROL 4.5MCG TURBUHALER

Dosage:

-**Asthma**: Oral inhalation:

-U.S. labeling**:** Symbicort® 80/4.5, Symbicort® 160/4.5: Two inhalations twice daily (maximum: 4 inhalations/day). Recommended starting dose combination is determined according to asthma severity. In patients not adequately controlled on the lower combination dose following 1-2 weeks of therapy, consider the higher dose combination.

-Canadian labeling:

-Symbicort® 100 Turbuhaler® [CAN; not available in U.S.], Symbicort® 200 Turbuhaler® [CAN; not available in U.S.]:

-Initial: 1-2 inhalations twice daily until symptom control, then titrate to lowest effective dosage to maintain control

-Maintenance: 1-2 inhalations once or twice daily (maximum: 8 inhalations/day as temporary treatment in periods of worsening asthma)

-Symbicort® Maintenance and Reliever Therapy (Symbicort® SMART): **Note:** Not approved in the U.S.:

-*Maintenance:* Symbicort® 100 Turbuhaler® [CAN] **or** Symbicort® 200 Turbuhaler® [CAN]: 1-2 inhalations twice daily **or** 2 inhalations once daily

-*Reliever therapy:* Symbicort® 100 Turbuhaler [CAN] **or** Symbicort® 200 Turbuhaler® [CAN]: 1 additional inhalation as needed, may repeat if no relief for up to 6 inhalations total (maximum: 8 inhalations/day)

-COPD: Oral inhalation:

-U.S. labeling: Symbicort® 160/4.5: Two inhalations twice daily (maximum: 4 inhalations/day)

-Canadian labeling: Symbicort® 200 Turbuhaler® [CAN; not available in U.S.]: Two inhalations twice daily (maximum: 4 inhalations/day).

Geriatric
Refer to adult dosing.

Renal Impairment:
No dosage adjustment provided in the manufacturer's labeling (has not been studied).

Hepatic Impairment:
No dosage adjustment provided in manufacturer's labeling (has not been studied). However, close monitoring of patients with hepatic disease may be warranted due to hepatic metabolism of both agents.

Common side effect:

Central nervous system: Headache

Respiratory: Nasopharyngitis , upper respiratory tract infections

Pregnancy Risk Factor: C